The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
Abstract
Cognitive abnormalities are common in Parkinson's disease, with important social and economic implications. Factors influencing their evolution remain unclear but are crucial to the development of targeted therapeutic strategies. We have investigated the development of cognitive impairment and dementia in Parkinson's disease using a longitudinal approach in a population-representative incident cohort (CamPaIGN study, n = 126) and here present the 5-year follow-up data from this study. Our previous work has implicated two genetic factors in the development of cognitive dysfunction in Parkinson's disease, namely the genes for catechol-O-methyltransferase (COMT Val(158)Met) and microtubule-associated protein tau (MAPT) H1/H2. Here, we have explored the influence of these genes in our incident cohort and an additional cross-sectional prevalent cohort (n = 386), and investigated the effect of MAPT H1/H2 haplotypes on tau transcription in post-mortem brain samples from patients with Lewy body disease and controls. Seventeen percent of incident patients developed dementia over 5 years [incidence 38.7 (23.9-59.3) per 1000 person-years]. We have demonstrated that three baseline measures, namely, age >or=72 years, semantic fluency less than 20 words in 90 s and inability to copy an intersecting pentagons figure, are significant predictors of dementia risk, thus validating our previous findings. In combination, these factors had an odds ratio of 88 for dementia within the first 5 years from diagnosis and may reflect the syndrome of mild cognitive impairment of Parkinson's disease. Phonemic fluency and other frontally based tasks were not associated with dementia risk. MAPT H1/H1 genotype was an independent predictor of dementia risk (odds ratio = 12.1) and the H1 versus H2 haplotype was associated with a 20% increase in transcription of 4-repeat tau in Lewy body disease brains. In contrast, COMT genotype had no effect on dementia, but a significant impact on Tower of London performance, a frontostriatally based executive task, which was dynamic, such that the ability to solve this task changed with disease progression. Hence, we have identified three highly informative predictors of dementia in Parkinson's disease, which can be easily translated into the clinic, and established that MAPT H1/H1 genotype is an important risk factor with functional effects on tau transcription. Our work suggests that the dementing process in Parkinson's disease is predictable and related to tau while frontal-executive dysfunction evolves independently with a more dopaminergic basis and better prognosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
The assessment of aphasia and related disorders
Goodglass, H., & Kaplan, E. (1972) · Medical Entomology and Zoology · Cited by 3,258
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Assessment of Aphasia and Related Disorders
Sarno, M. T. (1973) · Physical Therapy · doi:10.1093/ptj/53.2.225b · Cited by 2,242
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Cited by
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationParkinson disease-associated cognitive impairment
Aarsland, D., Batzu, L., Halliday, G. M., Geurtsen, G. J., Ballard, C., Ray Chaudhuri, K., & Weintraub, D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00280-3 · Cited by 1,371
Cognitive decline in Parkinson disease
Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.27 · Cited by 1,027
The MoCA: Well-suited screen for cognitive impairment in Parkinson disease
Dalrymple-Alford, J. C., MacAskill, M. R., Nakas, C. T., Livingston, L., Graham, C., Crucian, G. P., Melzer, T. R., Kirwan, J., Keenan, R., Wells, S., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181fc29c9 · Cited by 932
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 881
Self-citationParkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
Irwin, D. J., Lee, V. M.-Y., & Trojanowski, J. Q. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3549 · Cited by 869
MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI
Litvan, I., Aarsland, D., Adler, C. H., Goldman, J. G., Kulisevsky, J., Mollenhauer, B., Rodriguez‐Oroz, M. C., Tröster, A. I., & Weintraub, D. (2011) · Movement Disorders · doi:10.1002/mds.23823 · Cited by 805
Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis
Aarsland, D., Bronnick, K., Williams-Gray, C., Weintraub, D., Marder, K., Kulisevsky, J., Burn, D., Barone, P., Pagonabarraga, J., Allcock, L., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39d0e · Cited by 748
Self-citationThe CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort
Williams-Gray, C. H., Mason, S. L., Evans, J. R., Foltynie, T., Brayne, C., Robbins, T. W., & Barker, R. A. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-305277 · Cited by 681
Self-citationIdentifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits?
Helmich, R. C., Hallett, M., Deuschl, G., Toni, I., & Bloem, B. R. (2012) · Brain · doi:10.1093/brain/aws023 · Cited by 581
Walker, Z., Possin, K. L., Boeve, B. F., & Aarsland, D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00462-6 · Cited by 592
Cognitive Impairment in Parkinson’s Disease: The Dual Syndrome Hypothesis
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013) · Neurodegenerative Diseases · doi:10.1159/000341998 · Cited by 573
Self-citationThe cholinergic system and Parkinson disease
Bohnen, N. I., & Albin, R. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.12.048 · Cited by 566
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Svenningsson, P., Westman, E., Ballard, C., & Aarsland, D. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70152-7 · Cited by 499
Visual dysfunction in Parkinson’s disease
Weil, R. S., Schrag, A. E., Warren, J. D., Crutch, S. J., Lees, A. J., & Morris, H. R. (2016) · Brain · doi:10.1093/brain/aww175 · Cited by 481
“The underlying mechanism for these findings may relate to differences in the cortical expression of 4- versus 3repeat isoforms of tau (Williams-Gray et al., 2009).”
BackgroundInfluentialEFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease
Berardelli, A., Wenning, G. K., Antonini, A., Berg, D., Bloem, B. R., Bonifati, V., Brooks, D., Burn, D. J., Colosimo, C., Fanciulli, A., et al. (2013) · European Journal of Neurology · doi:10.1111/ene.12022 · Cited by 489
Advances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 466
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Parkinson’s disease dementia: a neural networks perspective
Gratwicke, J., Jahanshahi, M., & Foltynie, T. (2015) · Brain · doi:10.1093/brain/awv104 · Cited by 435
Self-citationMhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_16 · Cited by 423
Parkinson's disease: The quintessential neuropsychiatric disorder
Weintraub, D., & Burn, D. J. (2011) · Movement Disorders · doi:10.1002/mds.23664 · Cited by 423
Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study
Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., Nombela, C., Winder-Rhodes, S., Evans, J. R., Rowe, J. B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000066 · Cited by 422
Self-citationAthauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
Self-citationAre dementia with Lewy bodies and Parkinson’s disease dementia the same disease?
Jellinger, K. A., & Korczyn, A. D. (2018) · BMC Medicine · doi:10.1186/s12916-018-1016-8 · Cited by 385
CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease
Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Shaw, L. M., Van Deerlin, V., Trojanowski, J. Q., & Clark, C. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f39a78 · Cited by 378
Non motor subtypes and Parkinson's disease
Sauerbier, A., Jenner, P., Todorova, A., & Chaudhuri, K. R. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.027 · Cited by 375
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
Barker, R. A., Barrett, J., Mason, S. L., & Björklund, A. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70295-8 · Cited by 365
Self-citationPremotor and nonmotor features of Parkinson's disease
Goldman, J. G., & Postuma, R. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000112 · Cited by 343
The Epidemiology of Dementia Associated with Parkinson's Disease
Aarsland, D., & Kurz, M. W. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00369.x · Cited by 338
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Self-citationNonmotor features of Parkinson's disease subtypes
Marras, C., & Chaudhuri, K. R. (2016) · Movement Disorders · doi:10.1002/mds.26510 · Cited by 325
Cognitive impairment and resting-state network connectivity in Parkinson's disease
Baggio, H.-C., Segura, B., Sala-Llonch, R., Marti, M.-J., Valldeoriola, F., Compta, Y., Tolosa, E., & Junqué, C. (2015) · Human Brain Mapping · doi:10.1002/hbm.22622 · Cited by 320
Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud, S., Jones, D. R., Moussaud-Lamodière, E. L., Delenclos, M., Ross, O. A., & McLean, P. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-43 · Cited by 287
Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study
Pedersen, K. F., Larsen, J. P., Tysnes, O.-B., & Alves, G. (2017) · Neurology · doi:10.1212/wnl.0000000000003634 · Cited by 267
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264
Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's
Liu, G., Boot, B., Locascio, J. J., Jansen, I. E., Winder‐Rhodes, S., Eberly, S., Elbaz, A., Brice, A., Ravina, B., van Hilten, J. J., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24781 · Cited by 263
Self-citationMak, E., Su, L., Williams, G. B., Firbank, M. J., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Owen, A. M., Khoo, T. K., Brooks, D. J., et al. (2015) · Brain · doi:10.1093/brain/awv211 · Cited by 260
Self-citationCognitive impairment and dementia in Parkinson's disease
Pagonabarraga, J., & Kulisevsky, J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.029 · Cited by 257
Kotagal, V., Albin, R. L., Müller, M. L. T. M., Koeppe, R. A., Chervin, R. D., Frey, K. A., & Bohnen, N. I. (2012) · Annals of Neurology · doi:10.1002/ana.22691 · Cited by 253
Longitudinal study of normal cognition in Parkinson disease
Pigott, K., Rick, J., Xie, S. X., Hurtig, H., Chen-Plotkin, A., Duda, J. E., Morley, J. F., Chahine, L. M., Dahodwala, N., Akhtar, R. S., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000002001 · Cited by 251
Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective
Robbins, T. W., & Cools, R. (2014) · Movement Disorders · doi:10.1002/mds.25853 · Cited by 235
Self-citationLiu, G., Peng, J., Liao, Z., Locascio, J. J., Corvol, J.-C., Zhu, F., Dong, X., Maple-Grødem, J., Campbell, M. C., Elbaz, A., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00847-6 · Cited by 127
“13 cohorts enrolled patients with a diagnosis of PD established according to modified UK PD Society Brain Bank diagnostic criteria as previously reported 1,23,26,29,61,62,64–67 .”
Self-citationMisconceptions about speech impairment in Parkinson's disease
Moreau, C., & Pinto, S. (2019) · Movement Disorders · doi:10.1002/mds.27791 · Cited by 43
Structural Brain Correlations of Visuospatial and Visuoperceptual Tests in Parkinson’s Disease
Garcia-Diaz, A. I., Segura, B., Baggio, H. C., Marti, M. J., Valldeoriola, F., Compta, Y., Bargallo, N., Uribe, C., Campabadal, A., Abos, A., et al. (2018) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617717000583 · Cited by 39
“In later stages, visuospatial deficits emerge and have been associated with incident dementia in longitudinal population-based studies (Williams-Gray, Foltynie, Brayne, Robbins, & Barker, 2007; Williams-Gray et al., 2009, 2013).”
BackgroundRay, N. J., & Strafella, A. P. (2012) · Movement Disorders · doi:10.1002/mds.25173 · Cited by 35
Genome-wide determinants of mortality and motor progression in Parkinson’s disease
Tan, M. M. X., Lawton, M. A., Pollard, M. I., Brown, E., Real, R., Carrasco, A. M., Bekadar, S., Jabbari, E., Reynolds, R. H., Iwaki, H., et al. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00729-8 · Cited by 17
Self-citationThe Neurochemical Modulation of Prefrontal Control Processes
Robbins, T. W., & Kehagia, A. A. (2017) · The Wiley Handbook of Cognitive Control · doi:10.1002/9781118920497.ch19 · Cited by 4
Self-citation
Metadata
- Authors
- Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., Brayne, C., Kolachana, B. S., Weinberger, D. R., Sawcer, S. J., & Barker, R. A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-10-07
- Volume
- 132
- Issue
- 11
- Pages
- 2958-2969
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W1987003014
- Cited by
- 965
- References
- 78
- FWCI
- 23.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.